

FROMMER LAWRENCE & HAUG LLP

745 FIFTH AVENUE NEW YORK, NEW YORK 10151

TEL: (212) 588-0800 FAX: (212) 588-0500

3613 6 MAR -9 19:19

WILLIAM S. FROMMER
WILLIAM F. LAWRENCE
EDGAR H. HAUG
MATTHEW K. RYAN
BARRY S. WHITE
THOMAS J. KOWALSKI
JOHN R. LANE
DANIEL G. BROWN
STEVEN M. AMUNDSON
MARILYN MATTHES BROGAN
JAMES K. STRONSKI
CHARLES J. RAUBICHECK
GRACE L. PAN*
JEFFREY A. HOVDEN
RONALD R. SANTUCCI
RICHARD E. PARKE
LEONARD J. SANTISI
PORTER F. FLEMING
JOHN G. TAYLOR
KEVIN F. MURPHY
ARTHUR L. HOAG
SANDRA KUZMICH, PH.D.
STEPHEN J. LIEB

March 7, 2006

BY FEDERAL EXPRESS

Division of Dockets Management (HFA-305)
U.S. Food and Drug Administration
Room 1061
5630 Fishers Lane
Rockville, MD 20852

Re: **Docket No. 2005P-0436; NDA 21-863;**
Ibuprofen Liquid Filled Gelatin Capsules

We are counsel to Banner Pharmacaps Inc., on whose behalf we filed the above-referenced Citizen Petition, which was docketed on October 28, 2006.

We have just received the comments on the Petition by Buc & Beardsley, counsel for Ranbaxy Laboratories, Inc. These comments were docketed on February 28, 2006 (a link has not yet appeared on FDA's website).

This is to advise that Banner will file a Supplement to this Citizen Petition, replying to Ranbaxy's comments.

It is respectfully requested that no decision be made on Banner's Petition until FDA has reviewed and evaluated Banner's Supplement. The Supplement will be submitted well before April 28, 2006, the 180-day period for FDA to rule on the Petition under 21 C.F.R. §10.30(e)(2).

Sincerely yours,



Charles J. Raubicheck

Of Counsel
A. THOMAS S. SAFFORD
BARBARA Z. MORRISSEY

ROBERT E. COLLETTI
DEENA LEVY WEINHOUSE
DARREN M. SIMON
DAVID A. ZWALLY
PEARL TENG LINC SIEW
JOYCE W. LUK
DILLON KIM
LESLIE C. ALLEN*
NATHAN D. WEBER
SAMUEL S. LEE*
MAGALI ROZENFELD
H. SARAH PARK
SCOTT A. CLARK
THOMAS F. PRESSON
BRIAN J. MALKIN
JOHN J. MOLENDIA, PH.D.
SEAN E. RYDER*
JENNIFER CHUNG
JOHN S. GOETZ
CHIEMI D. SUZUKI
THOMAS A. NEYARAPALLY
KIMBERLY J. MCGRAW
JAMES E. BAUERSMITH*
DEBORAH L. LU, PH.D.
FRANCISCUS LADEJOLA-DIABA
PAUL A. LEVY
ANTONIO PAPAGEORGIU
ANTHONY D. MUSTILLO
DAVID HERMAN
VICKI FRANKS

CJR:Bav

cc: Charles Ganley, M.D.
Director, FDA Division of Over-the-Counter Drug Products (HFD-560)

Elizabeth H. Dickinson, Esq.
FDA Office of Chief Counsel (GCF-1)

*Admitted to a Bar other than New York

2005P-0436

LET 1

Division of Dockets Management (HFA-305)
U.S. Food and Drug Administration
March 7, 2006
Page 2

Leah A. Christl, FDA Division of
Over-the-Counter Drug Products (HFD-560)

Buc & Beardsley, Esqs.

Banner Pharmacaps Inc.